Company launches new project; strategic partnership established with Sichuan Jisheng Biopharmaceuticals.

ENTAI TRADING and Sichuan Jisheng Biopharmaceutical Co., Ltd. officially signed a strategic cooperation agreement on 2026/4/2, marking a key step in the company's strategic expansion into the pharmaceutical intermediates sector.

This collaboration is driven by the growing global demand for customized peptide products. Sichuan Jisheng Biopharmaceutical Co., Ltd., a leading domestic developer and manufacturer of peptide products, brings advanced synthesis technology and a comprehensive quality management system. ENTAI TRADING contributes its global sales network and professional supply chain capabilities. Together, the two parties will leverage complementary strengths.

Pursuant to the agreement, both parties will jointly invest R&D resources to develop high-value-added custom peptide products. These products will primarily serve innovative drug development, biomarker research, and diagnostic reagents. The first phase of product development is scheduled to launch in the second half of 2026, with mass production and market launch planned for 2027.

ENTAI TRADING's General Manager stated: "This partnership is a key strategic move to deepen our presence in the pharmaceutical intermediates sector. By joining forces with Jisheng Biopharm, we can offer global pharmaceutical clients a broader range of higher-quality peptide products, further strengthening our competitive edge in the chemical trading industry."

A representative from Sichuan Jisheng Biopharmaceuticals stated, "We chose to partner with ENTAI TRADING for its strong international market channels and professional service capabilities. Through this collaboration, our peptide products will better reach global markets and serve customers worldwide."

This collaboration also includes multiple dimensions such as technical exchange, market information sharing, and joint participation in international exhibitions. Both parties will establish a regular communication mechanism to ensure the smooth progress of the project.

Industry analysts note that this partnership aligns with the broader trend of resource integration and collaborative growth in the chemical trading sector. As the global pharmaceutical industry continues to expand, demand for high-quality pharmaceutical intermediates is expected to rise. This collaboration is poised to deliver significant commercial value for both parties.